IMGM Laboratories has purchased a Fluidigm Access Array System (AAS) to use in its development and validation of targeted re-sequencing applications services.
IMGM is the first genomic services provider to offer the combination of the Fluidigm Access Array technology in conjunction with Roche's 454 next-generation sequencing systems to its customers in Germany.
The access array technology provides parallel amplification of 48 unique samples, in effect preparing 48 sequencing libraries, in just a few hours.
Every reaction combines both an amplicon tagging and a barcoding (identification) step that enables all 48 amplicons to be multiplexed in a sequencing run.
The access array technology simplifies the labour-intensive up-front preparation, minimises preparation error and allows for the maximum utility of next generation sequencers.
IMGM implemented the Fluidigm Access Array System into its amplicon-based targeted re-sequencing workflow using the Roche 454 NGS sequencing technology and now offer its customers complete assay development solutions for Fluidigm-based target enrichment and library generation.
According to Fluidigm, harnessing and applying the power of NGS to targeted resequencing of multiple sample sets fills an important application need.
The company added that having good service providers such as IMGM, which spread the use of these capabilities, will allow more customers to take advantage of these combined tools.
IMGM offers advanced genomic services tailored to the needs of customers from pharmaceuticals, diagnostics, academia and biotech.
Expert bioinformatics and understandable reports add further value to these services.
It is accredited according to DIN EN ISO/IEC 17025 with a full accreditation for gene expression analysis based on microarrays and qPCR.
